Reimbursement Past Sema denied as non-formulary by Aetna?

Aetna's specific coverage criteria for reimbursement past sema are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Past Semaglutide Claims as Non-Formulary

A non-formulary denial for a retrospective semaglutide reimbursement claim means that, at the time of dispensing, semaglutide was not on the covered-drug tier of the patient's specific Aetna plan formulary — or that it required a formulary exception that was never requested. This is a plan-design issue rather than a clinical one, but it is still fully appealable because: (1) formulary placement can be challenged through a formulary exception process; (2) the drug may have been on a different formulary tier than the pharmacy billed; or (3) the plan's formulary may have changed between the plan year and the date the claim was submitted, creating a timing discrepancy.

## Why Non-Formulary Denials Are Routinely Appealed Successfully

Aetna (and all ACA-compliant plans) must have a formulary exception process. A formulary exception grants access to a non-formulary drug at in-plan cost-sharing when the patient's prescriber documents that all covered formulary alternatives are clinically inappropriate for that patient. For retrospective claims, the exception can sometimes be granted retroactively if the clinical rationale is compelling. Additionally, if the patient could not tolerate or did not respond to the formulary alternatives, that history is central to the exception argument.

## Federal Appeal Framework

• Formulary exception request (concurrent with or prior to appeal): Submit a prescriber-supported formulary exception request if one was never filed. This is a separate administrative pathway that can resolve the denial without a formal appeal.
• Internal appeal: File within 180 days of the denial. Frame the appeal as both a formulary exception and a standard coverage appeal.
• External review (ACA §2719): Available after internal exhaustion, within approximately four months of final denial. IROs can order formulary exceptions when the clinical record supports it. Binding on Aetna.
• ERISA §503: Full-and-fair review rights apply to self-funded employer plans.

## Documentation to Gather

1. Aetna's formulary document for the plan year at issue — confirm whether semaglutide was listed and, if so, at what tier and with what restrictions. 2. EOB and pharmacy dispensing record — confirm the NDC billed, the tier applied, and the cost-sharing charged. 3. Prescriber's formulary exception letter — a signed letter explaining why each covered formulary alternative (by class or mechanism, without needing to name the generic) is clinically inappropriate for this patient, citing diagnosis, comorbidities, and any prior trial and failure of a formulary alternative. 4. Prior trial and failure documentation — chart notes or pharmacy records showing any covered alternative that was tried and either failed to achieve therapeutic goals or caused intolerable side effects. 5. Diagnosis and severity records — confirming the qualifying condition and the clinical urgency that justified prescribing a non-formulary agent rather than waiting for a prospective exception approval.

## Criteria-Mapping Structure

For the formulary exception argument, address each covered formulary alternative explicitly: whether it was tried (with dates and outcome) or why it was not tried (clinical contraindication or inappropriateness per the prescriber). Aetna's formulary exception criteria require this alternative-by-alternative analysis; provide it in tabular form with chart references as exhibits.